Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy by Michael B Atkins, Michael T Serzan, Princy N Kumar

Get full text

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma by James Brugarolas, Michael B Atkins, Brian I Rini

Get full text

Braincase simplification and the origin of lissamphibians. by Jade B Atkins, Robert R Reisz, Hillary C Maddin

Get full text

Management of metastatic renal cell carcinoma in patients with poor prognosis by Andrea Bullock, David F McDermott, Michael B Atkins

Get full text

Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts? by Eric Jonasch, Michael B. Atkins, Simon Chowdhury, Paul Mainwaring

Get full text

A case of checkpoint inhibitor-induced celiac disease by Dana Alsaadi, Neil J. Shah, Aline Charabaty, Michael B. Atkins

Get full text

Osteomyelitis of the Pelvic Bones: A Multidisciplinary Approach to Treatment by M. Dudareva, J. Ferguson, N. Riley, D. Stubbs, B. Atkins, M. McNally

Get full text

Dinner and a Conversation: Transgender Integration at West Point and Beyond by Morten G. Ender, Diane M. Ryan, Danielle A. Nuszkowski, Emma Sarah Spell, Charles B. Atkins

Get full text

Societal preferences for adjuvant melanoma health states: UK and Australia by Mark R. Middleton, Michael B. Atkins, Kaitlan Amos, Peter Feng Wang, Srividya Kotapati, Javier Sabater, Kathleen Beusterien

Get full text

1317 Enhancing patient safety in melanoma treatment: harnessing machine learning for predicting immune-related adverse events by Samir Gupta, Michael B Atkins, Neil J Shah, Jacob Zaemes, Shaked Lev Ari, Yili Zhang, Adil Alaoui, Subha Madhavan, Peter McGarvey

Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis by Dongyu Zhang, Neil J. Shah, Michael Cook, Matthew Blackburn, Michael T. Serzan, Shailesh Advani, Arnold L. Potosky, Subha Madhavan, Anas Belouali, Michael B. Atkins, Dejana Braithwaite

Get full text

Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors:... by Dongyu Zhang, Neil J. Shah, Michael Cook, Matthew Blackburn, Michael T. Serzan, Shailesh Advani, Arnold L. Potosky, Subha Madhavan, Anas Belouali, Michael B. Atkins, Dejana Braithwaite

Get full text

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection by Neil J. Shah, Ghassan Al-Shbool, Matthew Blackburn, Michael Cook, Anas Belouali, Stephen V. Liu, Subha Madhavan, Aiwu Ruth He, Michael B. Atkins, Geoffrey T. Gibney, Chul Kim

Get full text

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting by Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton, Peter P. Yu

Get full text

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies by James L Gulley, Harriet Kluger, Hussein Tawbi, Jeffrey Sosman, Paolo A Ascierto, Michael B Atkins, Nikhil I Khushalani, Douglas B Johnson, Timonthy A Yap, Ryan J Sullivan, David Feltquate

Get full text

Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors by Suthee Rapisuwon, Benjamin Izar, Cory Batenchuk, Alexandre Avila, Shaolin Mei, Peter Sorger, Jerry M. Parks, Sarah J. Cooper, David Wagner, Jay C. Zeck, Aline J. Charabaty, Michael B. Atkins

Get full text

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma by Michael B. Atkins, Suthee Rapisuwon, Arash Radfar, Kellie Gardner, Neil J. Shah, Geoffrey T. Gibney, Jacob Zaemes, Shelly Shand, David Swoboda, Vesna Petronic-Rosic, Michael J. Reilly, Waddah B. Al-Refaie

Get full text

615 The impact of gender including female menopausal status on the safety and efficacy of immune checkpoint inhibitors by Michael B Atkins, Neil J Shah, Jacob Zaemes, Andrew Pecora, Shaked Lev Ari, Lauren Pascual, Brittany Sinclaire, Alexandra DellaPia, Rachel A Zemel, Adil Alaoui, Andrew Ip, Deniz Ozisik, Ming Tan

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs by Tian Zhang, Patrick M Forde, Elad Sharon, Scot Ebbinghaus, Michael B Atkins, Mark Stewart, Ryan J Sullivan, Elizabeth Barksdale, Wendy Selig, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert

Get full text

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. by Liang Zhang, Manoj Bhasin, Rachel Schor-Bardach, Xiaoen Wang, Michael P Collins, David Panka, Prabhakar Putheti, Sabina Signoretti, David C Alsop, Towia Libermann, Michael B Atkins, James W Mier, S Nahum Goldberg, Rupal S Bhatt

Get full text